D. P. E. A. liability

2079 SHRIMATI SATYA BAHIN : Will the PRIMP. MINISTER be pleased to refer to the answer to Unstarred question 1227 given in Rajya Sabha on 4-3-94 and stale :

(a) whether it is a fact that process of (.'ranting hearings to those having DPEA liability was started two and a half years back and none of (he cases have been finalised so far:

(b) if so, (he details of (he cases finalised ami what is the present status of each:

(c) what are the details of hearing granted to these parties up(o 15th July, 1993 and (he outcome of each hearing: and

(d) whe(her it is also a fact (hat no fresh liability has been assessed during this period and if so what steps have been taken to expedite the recovery?

Till- MINISTAR OF STATU IN THE MINSTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a)

No, Sir,

(b) and (c) The following cases have been finalised and orders for recoveries issued:

(Rs. in lakhs)

S. No.	Name of Cos.	Product	Amount Liability	Amount Deposited
1.	M/s Pfizer	Oxytatracyline	87.61	43.80
2.	M/s Pfizer	Multi-Vitamins	38.00	49.00
3.	M/s Sandoz	Multi-Vitamins	74.68	37.64
4.	M/s Abbot	Multi-Vitamins	182.38	91.15
5.	M/s Borroughs Wellcome	Sulphamethoxazole	191.15	NIL

After completing the hearings in cases at S. No. 1 to4 the orders were issued against which these companies filed writ petitions in the High Court and as per direction of the Court these companies have deposited 50%of their liabilities. In case of S. No. 5 the no(ice has been issued on 23-7-1993.

(d) Effort's are being made to obtain the data from the concerned companies and in case (he companies do no(furnish (he same, liability against them would be worked out on the basis of data available from other sources.

Price of Vitamin B6

2080. SHRI ANANT RAM JAISWAL : Will the PRIME MINISTER be pleased to state:

(a) whether IDPL have represented against the high price being charged for Vitamin B6 by the other producer and also import of the penultimates by the said producer:

(b) (he price being charged for Vitamin B6 by the two producers and (he details of imports of major intermediates made by them during last two years and the custom duty on such intermediates at present:

(c) the CIF import price of the drug at present and

(d) whether it is a fact that import of inter-inedi'fttes and penultimates has been allowed to one of the parties out of the way and if so, what are the reasons for the same ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) IDPL has brought to the notice of the Government cheaper imports of Vitamin B6 and the consequent reduction of prices of Vitamin B6 *by th*e other local manufacturer.

(b) to (d) Vitamin B6 is price-decontrolled as a bulk drug. Vitamin B6 as well as its inler-mediates can be imported without licence. At present the custom duty on the intermediate required for the manufacture of Vitamin B6 is leviable @ 50%. Imports of drug intermediates $_{are}$ not monitored.

Drug production by IDPL and HAL

2081 SHRI H. HANUMANTHAPPA: SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to state :

(a) the names of bulk drugs being pro by Indian Drugs and Pharmaceuticals L and Hindustan Antibiotics Limited and production of each during the last three yet year-wise;

(b) whether it is a fact that the production of
most of the items have declined:

(c) if so, what are the reasons therefor;

(d) whether it is a fact that IDPL is producing Vitamin B6 from imported intermediates having duly reduction:

(e) what was the production of this company during the last three years, year-wise and what was the increase in price announced by this company during the above period and what is the current price: and

(0 what are the names of other drugs being produced by these companies based on imported intermediates having reduction in duly?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO) : (a) The names of the bulk drugs produced by Indian Drugs & Pharmaceuticals Limited (IDPL) and Hindustan Antibiotics Limited (HAL) are given in the enclosed statements I and II *(See* below).

(b) and (c) The production of two bulk drugs out of the 6 being produced by HAL had registered decrease. The decrease in production of one of the bulk drugs, namely, Hamyctn is very marginal. The fall in the level of production of Gentamycin is because of non-profitability on account of availability of cheaper imported material in the market.

Out of 17 major bulk drugs produced by IDPL, the production of a bulk drugs registered a decrease in 1992-93. The decrease in production of 3 bulk drugs had been marginal. IDPL has been incurring losses over the years and as a result the working capital base of the company has eroded considerably. The fall in the level of production by IDPL in 1992-93 has been mainly because of the constraints of working capital.

(d) IDPL is producing Vitamin B6 from the basic stages by using very few imported raw materials and not from the penultimate intermediate stage. There is no specific duty reduction for IDPL only. The import duty is uniformly applicable to all manufacturers including IDPL.

(e) The details of production of Vitamin B6 during the last 3 years are given in the enclosed statement I *(See* below). The price revisions affected by the company during the last 3 years in respect of Vitamin B6 are indicated in the enclosed statement III *(See* below).

(0 IDPL is producing bulk drugs from basic stages. Chloroquin Phosphate, one of the bulk drugs, is being produced by using imported Novoldiamine like other manufacturers in India. Novoldiamine is not available indigenously. There is no duty reduction specially for IDPL. The import duty is applicable uniformly to all manufacturers including IDPL.

Statement I

Production of Key Sulk Drugs by I.D.P.L, during the Last Three Years

S. No.	Name of the Drug	Unit	Production		
			1990-91	1991-92	1992-93
1.	Potassium Penicillin	MMU	290.56	301.32	406.56
2.	*Sodium Penicillin*	MMU	9.04	12.94	14.40
3.	Procaine Penicillin	MMU	1.17	11.54	15.42
4.	Streptomycin Sulphate	T/Base	20.62	26.72	23.75
5.	Tetracycline	MT	108.54	66.79	56.60
6.	Oxytetracycline	MT	56.13	70.24	84.67
7.	Vitamin B1	MT	70.78	78.80	57.32
8.	Vitamin B2	MT	24.57	19.84	20.76
9.	Vitamin B6	MT	11.95	16.60	15.64
10.	Sulphadimidine/Sodium	MT	139.54	110.18	41.92

11.	Sulphaguanidine	MT	48.01	84.45	48.25
12.	Analgin	MT	8.30	261.30	13.80
13.	Folic Acid	MT	.94	3.21	10.98
14.	Acetazolamide	MT	6.31	4.06	11.93
15.	Chloroquine Phosphate	MT	33.75	30.15	5.75
16.	Methyl Dopa	MT	7.44	4.04	7.73
17.	Niacinamide	MT	61.85	100.40	102.55

Statement II

Production of Bulk Drugs by Hindustan Antibiotics Limited during the Last Three Years

S. No.	Name of the Drugs	Unit	Production		
			1990-91	1991-92	1992-93
1.	Penicillin First Crystals & Penicillin	MMU	546.5	640.5	713.1
2.	Bulk Penicillin	MMU	67.4	62.7	73.7
3.	Streptomycin	Tonnes	65.7	74.8	78.0
4.	Gentamycin	Kgs.	1635.0	841.5	87.9
5.	Hamycin	Kgs.	14.0	12.6	11.8
6.	6APA	Tonnes	2.2	5.5	8.0

Statement III

Price increase announced by IDPL in respect of Vitamin B6 during the Lost Three Years

S. No.	Name of the Drug	Unit	Date of Revision	Rate/Unit (Rs.)
1.	VITAMIN B6	KG	13-12-1989	1400
			29-10-1990	1512
			22-10-1991	2000
			08-05-1992	2200
			17-06-1992	2600
			25-09-1992	2800

Recovery of overcharged amount of drugs

2082. SHRI H. HANUMANTHAPPA: SHRI ANANT RAM JAISWAL : Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1232 given in Rajya Sabha on 4th March, 1993 and state:

(a) whether it is a fact that Government have failed to recover the amounts overcharged by the producers of bulk, drugs or formulations even after the announcement of DPCO, J9S7;

(b) what are the instances of overcharging of prices which have come to the notice of Government after the announcement of DPCO, 1987 and the number of cases where overcharged amount has been recovered;

(c). what are the names of bulk drags and